Literature DB >> 32579820

Vasoactive Intestinal Peptide in Checkpoint Inhibitor-Induced Pneumonitis.

Björn C Frye1, Frank Meiss1, Dagmar von Bubnoff1, Gernot Zissel1, Joachim Müller-Quernheim1.   

Abstract

Year:  2020        PMID： 32579820     DOI： 10.1056/NEJMc2000343

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.

Authors:  Jihad Georges Youssef; Philip Lavin; David A Schoenfeld; Richard A Lee; Rainer Lenhardt; David J Park; Javier Perez Fernandez; Melvin L Morganroth; Jonathan C Javitt; Dushyantha Jayaweera
Journal:  Crit Care Med       Date:  2022-08-29       Impact factor: 9.296

2.  Cellular analysis of bronchoalveolar lavage fluid to narrow differential diagnosis of checkpoint inhibitor-related pneumonitis in metastatic melanoma.

Authors:  Sabino Strippoli; Livia Fucci; Antonio Negri; Daniela Putignano; Marco Luigi Cisternino; Gaetano Napoli; Ruggiero Filannino; Ivana De Risi; Angela Monica Sciacovelli; Michele Guida
Journal:  J Transl Med       Date:  2020-12-10       Impact factor: 5.531

3.  Brief Report: Rapid Clinical Recovery From Critical Coronavirus Disease 2019 With Respiratory Failure in a Pregnant Patient Treated With IV Vasoactive Intestinal Peptide.

Authors:  Jihad Georges Youssef; Mohammad Z Bitar; Faisal Zahiruddin; Mukhtar Al-Saadi; Mahmoud Elshawwaf; Simon Yau; Ahmad Goodarzi; Jonathan C Javitt
Journal:  Crit Care Explor       Date:  2022-01-05

4.  Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial.

Authors:  Maria Boesing; Kristin Abig; Michael Brändle; Martin Brutsche; Emanuel Burri; Björn C Frye; Stéphanie Giezendanner; Jan C Grutters; Philippe Haas; Justian Heisler; Fabienne Jaun; Anne B Leuppi-Taegtmeyer; Giorgia Lüthi-Corridori; Joachim Müller-Quernheim; Reto Nüesch; Wolfgang Pohl; Frank Rassouli; Jörg D Leuppi
Journal:  Trials       Date:  2022-09-20       Impact factor: 2.728
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.